Elucidating the Mechanism of Action and Potential Interactions of MAO-B Inhibitors

Neurologic Clinics

Volumn 26, Issue 3 SUPPL., 2008, Pages 85-96

  Bainbridge, Jacquelyn L ^a   Lee Page II, Robert ^b   Ruscin, J Mark ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; CAPTOPRIL; CARBAMAZEPINE; CHLORPROMAZINE; CYPROHEPTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESMOLOL; LABETALOL; LEVODOPA; LITHIUM; METOCLOPRAMIDE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NIFEDIPINE; NITROPRUSSIDE SODIUM; ONDANSETRON; PETHIDINE; PLACEBO; RASAGILINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNINDEXED DRUG; VENLAFAXINE;

BRAIN REGION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MECHANISM; ENZYME INHIBITION; FOOD DRUG INTERACTION; HUMAN; HYPERTENSIVE CRISIS; MAJOR DEPRESSION; MONOTHERAPY; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 50649103994     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2008.05.002     Document Type: Review

References (47)

1. Youdim M.B., and Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147 Suppl 1 (2006) S287-S296
2. Tipton K.F., Boyce S., O'Sullivan J., et al. Monoamine oxidases: certainties and uncertainties. Curr Med Chem 11 (2004) 1965-1982
3. Johnston J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17 (1968) 1285-1297
4. Nicotra A., Pierucci F., Parvez H., et al. Monoamine oxidase expression during development and aging. Neurotoxicology 25 (2004) 155-165
5. Collins G.G., Sandler M., Williams E.D., et al. Multiple forms of human brain mitochondrial monoamine oxidase. Nature 225 (1970) 817-820
6. O'Carroll A.M., Fowler C.J., Phillips J.P., et al. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 322 (1983) 198-202
7. Westlund K.N., Denney R.M., Kochersperger L.M., et al. Distinct monoamine oxidase A and B populations in primate brain. Science 230 (1985) 181-183
8. Arai R., Karasawa N., Kurokawa K., et al. Differential subcellular location of mitochondria in rat serotonergic neurons depends on the presence and the absence of monoamine oxidase type B. Neuroscience 114 (2002) 825-835
9. Eriksson H., Lenngren S., and Heilbronn E. Effect of long-term administration of manganese on biogenic amine levels in discrete striatal regions of rat brain. Arch Toxicol 59 (1987) 426-431
10. Koepsell H. Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci 25 (2004) 357-381
11. Tipton K. Biochemical aspects of monoamine oxidase. Br Med Bull 29 (1973) 116-119
12. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 (1993) 176-183
13. Nagatsu T., and Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. J Neural Transm 71 S (2006) 53-65
14. Fowler C.J., Wiberg A., Oreland L., et al. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49 (1980) 1-20
15. Dexter D.T., Wells F.R., Agid F., et al. Increased nigral iron content in postmortem parkinonian brain. Lancet 2 (1987) 1219-1220
16. Hirsch E.C., Brandel J.P., Galle P., et al. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56 (1991) 446-451
17. Cohen G. Oxygen radicals and Parkinson's disease. Neurology 38 (1988) 130-135
18. Gerlach M., Riederer P., and Youdim M.B. The molecular pharmacology of L-deprenyl. Eur J Pharmacol 226 (1992) 97-108
19. Mizuta I., Ohta M., Ohta K., et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 279 (2000) 751-755
20. Tatton W., Chalmers-Redman R., and Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehydes-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 110 (2003) 509-515
21. Youdim M.B., Bar Am O., Yogev-Falach M., et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79 (2005) 172-179
22. Maruyama W., Nitta A., Shamoto-Nagai M., et al. N-propargyl-1(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor GDNF in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 44 (2004) 393-400
23. Bar-Am O., Amit T., and Youdim M.B. Contrasting neuroprotective and neurotoxic action of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355 (2004) 169-172
24. Abu-Raya S., Tabakman R., Blaugrund E., et al. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 434 (2002) 109-116
25. Goggi J., Theofilipoulos S., Riaz S.S., et al. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat vental mesencephalic neurons in culture. Neuroreport 11 (2000) 3937-3941
26. Tetrud J.W., and Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245 (1989) 519-522
27. Myllyla V.V., Sotaniemi K.A., Vuorinen J.A., et al. Selegiline as a primary treatment of Parkinson's disease. Acta Neurol Scand Suppl 136 (1991) 70-72
28. Palhagan S., Heinonen E.H., Hagglund J., et al. Swedish Parkinson Study Group. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 51 (1998) 520-525
29. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 (2004) 561-566
30. Shulman K.I., Walker S.E., MacKenzie S., et al. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 9 6 (1989) 397-402
31. Golwyn D.H., and Sevlie C.P. Monoamine oxidase inhibitor hypertensive crisis headache: prevention and treatment. Headache Quarterly - Current Treatment and Research 7 3 (1996) 207-214
32. Fernandez H.H., and Chen J.J. Monoamine oxidase inhibitors: current and emerging agents for Parkinson Disease. Clin Neuropharmacol 30 (2007) 150-168
33. Brown C.S., and Bryant S.G. Monoamine oxidase inhibitors: safety and efficacy issues. Drug Intell Clin Pharm 22 (1988) 232-235
34. Marcason W. What is the bottom line for dietary guidelines when taking monoamine oxidase inhibitors?. J Am Diet Assoc 105 (2005) 163
35. Neil J.F., Licata S.M., May S.J., et al. Dietary noncompliance during treatment with tranylcypromine. J Clin Psychiatry 40 (1979) 33-37
36. deMarcaida J.A., Schwid S.R., White W.B., et al. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 21 10 (2006) 1716-1721
37. Data on file, Teva Neuroscience, Inc., 2008.
38. White W.B., deMarcaida A., Salzman P., et al. Rasagiline does not affect blood pressure in Parkinson's disease (PD) patients following meals unrestricted in dietary tyramine content: results from over 25,000 trans-telephonic blood pressure measurements in 443 patients. Neurology 66 Suppl 2 (2006) A314-A315
39. Guillaume M, Thebault JJ, Cohen S. Assessment of the potential for pharmacodynamic interaction between rasagiline and oral tyramine in healthy subjects. Presented at The Movement Disorder Society's 10th International Congress of Parkinson's Disease and movement disorders. Kyoto, Japan, October 28-November 2, 2006. Mov Disord 2006;21(Suppl 15):S594.
40. Grossman E., Messerli F.H., Grodzicki T., et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?. JAMA 276 (1996) 1328-1331
41. Varon J., and Marik P.E. The diagnosis and management of hypertensive crisis. Chest 118 (2000) 214-227
42. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42 (2003) 1206-1252
43. Boyer E.W., and Shannon M. The serotonin syndrome. N Engl J Med 352 (2005) 1112-1120
44. Sporer K.A. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 2 (1995) 94-104
45. Ganetsky M., and Brush D.E. Serotonin syndrome-what have we learned?. Clin Pediatr Emerg Med 6 (2005) 103-108
46. Eldepryl [package insert]. Tampa (FL): Somerset Pharmaceuticals; 1997.
47. Gillman P.K. The serotonin syndrome and its treatment. J Psychopharmacol 13 (1999) 100-103